Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy

* Participants with moderate to severe chronic plaque psoriasis defined as Psoriasis Area and Severity Index (PASI) ≥ 10 and body surface area ≥ 10% with or without psoriatic arthritis, who have an adalimumab therapy indication because they are candidates for systemic therapy or phototherapy and other systemic therapies are medically less appropriate * Participant is capable of and willing to give written informed consent and to comply with the requirements of the study protocol

* Participants should not be enrolled if they cannot be treated in accordance with the local product label * Participants enrolled into another study or clinical trial * History of hepatitis B infection * History of neurologic symptoms suggestive of central nervous system demyelinating disease * History of cancer or lymphoproliferative disease (other than successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix) * Active tuberculosis infection before initiating adalimumab treatment or latent tuberculosis infection not able to take complete prophylactic treatment * Pregnant or lactating female, demonstrated by a pregnancy test before entering the study and willing to use a contraceptive method * Use of another anti-tumoral necrosis factor previously * History of congestive heart failure * Any other condition that according to the criteria of the participating investigator represents an obstacle for study conduction and/or subjects participants to an unacceptable risk * Participants with active infection including chronic or localized infections until infections are controlled * History of sensitivity to latex * Participants who will receive concomitant phototherapy and systemic therapy during adalimumab therapy